1	Bevacizumab	Bevacizumab	B-NP	NN	O	4	NMOD	0
2	and	and	I-NP	CC	O	4	NMOD	0
3	irinotecan	irinotecan	I-NP	NN	O	4	NMOD	0
4	therapy	therapy	I-NP	NN	O	10	NMOD	19	therapy
5	in	in	B-PP	IN	O	4	NMOD	0
6	glioblastoma	glioblastoma	B-NP	NN	O	7	NMOD	0
7	multiforme	multiforme	I-NP	NN	O	5	PMOD	0
8	:	:	O	:	O	4	P	0
9	a	a	B-NP	DT	O	10	NMOD	0
10	series	series	I-NP	NN	O	0	ROOT	0
11	of	of	B-PP	IN	O	10	NMOD	0
12	13	13	B-NP	CD	O	13	NMOD	0
13	cases	case	I-NP	NNS	O	11	PMOD	0
14	.	.	O	.	O	10	P	0

1	OBJECT	OBJECT	B-NP	NN	O	4	NMOD	0
2	:	:	O	:	O	1	P	0
3	Endothelial	Endothelial	B-NP	JJ	O	4	NMOD	0
4	proliferation	proliferation	I-NP	NN	O	5	SUB	1	proliferation
5	has	have	B-VP	VBZ	O	0	ROOT	0
6	been	be	I-VP	VBN	O	5	VC	0
7	recognized	recognize	I-VP	VBN	O	6	VC	0
8	as	as	B-PP	IN	O	7	VMOD	0
9	a	a	B-NP	DT	O	10	NMOD	0
10	marker	marker	I-NP	NN	O	8	PMOD	0
11	of	of	B-PP	IN	O	10	NMOD	0
12	high-grade	high-grade	B-NP	JJ	O	15	NMOD	0
13	or	or	I-NP	CC	O	15	NMOD	0
14	aggressive	aggressive	I-NP	JJ	O	15	NMOD	0
15	glioma	glioma	I-NP	NN	O	11	PMOD	0
16	.	.	O	.	O	5	P	0

1	Bevacizumab	Bevacizumab	B-NP	NNP	O	2	SUB	0
2	is	be	B-VP	VBZ	O	0	ROOT	0
3	a	a	B-NP	DT	O	8	NMOD	0
4	humanized	humanized	I-NP	JJ	B-protein	8	NMOD	0
5	immunoglobulin	immunoglobulin	I-NP	NN	I-protein	8	NMOD	0
6	G1	G1	I-NP	NN	I-protein	8	NMOD	0
7	monoclonal	monoclonal	I-NP	JJ	I-protein	8	NMOD	0
8	antibody	antibody	I-NP	NN	I-protein	2	PRD	0
9	to	to	B-PP	TO	O	8	NMOD	0
10	vascular	vascular	B-NP	JJ	B-protein	13	NMOD	0
11	endothelial	endothelial	I-NP	JJ	I-protein	13	NMOD	0
12	growth	growth	I-NP	NN	I-protein	13	NMOD	0
13	factor	factor	I-NP	NN	I-protein	9	PMOD	0
14	that	that	B-NP	WDT	O	13	NMOD	0
15	has	have	B-VP	VBZ	O	14	SBAR	0
16	been	be	I-VP	VBN	O	15	VC	0
17	shown	show	I-VP	VBN	O	16	VC	0
18	to	to	I-VP	TO	O	19	VMOD	0
19	have	have	I-VP	VB	O	17	VMOD	0
20	activity	activity	B-NP	NN	O	19	OBJ	0
21	in	in	B-PP	IN	O	19	VMOD	0
22	malignant	malignant	B-NP	JJ	B-cell_type	23	NMOD	0
23	gliomas	glioma	I-NP	NNS	I-cell_type	21	PMOD	0
24	when	when	B-ADVP	WRB	O	19	VMOD	0
25	combined	combine	B-VP	VBN	O	24	SBAR	0
26	with	with	B-PP	IN	O	25	VMOD	0
27	irinotecan	irinotecan	B-NP	NN	O	26	PMOD	0
28	.	.	O	.	O	2	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	authors	author	I-NP	NNS	O	3	SUB	0
3	report	report	B-VP	VBP	O	0	ROOT	0
4	on	on	B-PP	IN	O	3	VMOD	0
5	a	a	B-NP	DT	O	7	NMOD	0
6	case	case	I-NP	NN	O	7	NMOD	0
7	series	series	I-NP	NN	O	4	PMOD	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	13	13	B-NP	CD	O	10	NMOD	0
10	patients	patient	I-NP	NNS	O	8	PMOD	0
11	with	with	B-PP	IN	O	10	NMOD	0
12	recurrent	recurrent	B-NP	JJ	O	14	AMOD	0
13	heavily	heavily	I-NP	RB	O	14	AMOD	0
14	pretreated	pretreated	I-NP	JJ	O	16	NMOD	19	pretreated
15	malignant	malignant	I-NP	JJ	O	16	NMOD	0
16	glioma	glioma	I-NP	NN	O	11	PMOD	0
17	that	that	B-NP	WDT	O	7	NMOD	0
18	was	be	B-VP	VBD	O	17	SBAR	0
19	treated	treat	I-VP	VBN	O	18	VC	19	treated
20	with	with	B-PP	IN	O	19	VMOD	0
21	the	the	B-NP	DT	O	22	NMOD	0
22	combination	combination	I-NP	NN	O	20	PMOD	0
23	of	of	B-PP	IN	O	22	NMOD	0
24	bevacizumab	bevacizumab	B-NP	NN	O	26	NMOD	0
25	and	and	I-NP	CC	O	26	NMOD	0
26	irinotecan	irinotecan	I-NP	NN	O	23	PMOD	0
27	.	.	O	.	O	3	P	0

1	METHODS	METHODS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Standard	Standard	B-NP	JJ	O	4	NMOD	0
4	therapy	therapy	I-NP	NN	O	14	SUB	0
5	with	with	B-PP	IN	O	4	NMOD	0
6	primary	primary	B-NP	JJ	O	7	NMOD	0
7	resection	resection	I-NP	NN	O	5	PMOD	0
8	followed	follow	B-VP	VBN	O	4	NMOD	0
9	by	by	B-PP	IN	O	8	VMOD	0
10	adjuvant	adjuvant	B-NP	JJ	O	11	NMOD	0
11	chemotherapy	chemotherapy	I-NP	NN	O	13	NMOD	19	chemotherapy
12	and	and	I-NP	CC	O	13	NMOD	0
13	radiation	radiation	I-NP	NN	O	9	PMOD	19	radiation
14	had	have	B-VP	VBD	O	1	NMOD	0
15	failed	fail	I-VP	VBN	O	14	VC	0
16	in	in	B-PP	IN	O	15	VMOD	0
17	all	all	B-NP	DT	O	18	NMOD	0
18	patients	patient	I-NP	NNS	O	16	PMOD	0
19	.	.	O	.	O	1	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	median	median	I-NP	JJ	O	3	NMOD	0
3	number	number	I-NP	NN	O	12	SUB	0
4	of	of	B-PP	IN	O	3	NMOD	0
5	therapies	therapy	B-NP	NNS	O	4	PMOD	0
6	applied	apply	B-VP	VBN	O	5	NMOD	0
7	,	,	O	,	O	3	P	0
8	including	include	B-PP	VBG	O	3	NMOD	0
9	initial	initial	B-NP	JJ	O	10	NMOD	0
10	surgery	surgery	I-NP	NN	O	8	PMOD	0
11	,	,	O	,	O	3	P	0
12	was	be	B-VP	VBD	O	0	ROOT	0
13	5	5	B-NP	CD	O	12	PRD	0
14	(	(	O	(	O	18	DEP	0
15	range	range	B-NP	NN	O	17	NMOD	0
16	3-7	3-7	B-NP	CD	O	17	NMOD	0
17	therapies	therapy	I-NP	NNS	O	18	DEP	0
18	)	)	O	)	O	13	NMOD	0
19	.	.	O	.	O	12	P	0

1	Nine	Nine	B-NP	CD	O	2	NMOD	0
2	patients	patient	I-NP	NNS	O	3	SUB	0
3	were	be	B-VP	VBD	O	0	ROOT	0
4	started	start	I-VP	VBN	O	3	VC	19	started
5	on	on	B-PP	IN	O	4	VMOD	0
6	bevacizumab	bevacizumab	B-NP	NN	O	5	PMOD	0
7	at	at	B-PP	IN	O	6	NMOD	0
8	a	a	B-NP	DT	O	9	NMOD	0
9	dose	dose	I-NP	NN	O	7	PMOD	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	5	5	B-NP	CD	O	12	NMOD	0
12	mg/m2	mg/m2	I-NP	NN	O	10	PMOD	0
13	every	every	B-NP	DT	O	15	NMOD	0
14	2	2	I-NP	CD	O	15	NMOD	0
15	weeks	week	I-NP	NNS	O	4	VMOD	0
16	.	.	O	.	O	3	P	0

1	Four	Four	B-NP	CD	O	2	NMOD	0
2	patients	patient	I-NP	NNS	O	3	SUB	0
3	received	receive	B-VP	VBD	O	13	VMOD	19	received
4	bevacizumab	bevacizumab	B-NP	NN	O	3	OBJ	0
5	at	at	B-PP	IN	O	3	VMOD	0
6	a	a	B-NP	DT	O	7	NMOD	0
7	dose	dose	I-NP	NN	O	5	PMOD	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	10	10	B-NP	CD	O	10	NMOD	0
10	mg/m2	mg/m2	I-NP	NN	O	8	PMOD	0
11	;	;	O	:	O	13	P	0
12	irinotecan	irinotecan	B-NP	NN	O	13	SUB	0
13	was	be	B-VP	VBD	O	0	ROOT	0
14	given	give	I-VP	VBN	O	13	VC	19	given
15	at	at	B-PP	IN	O	14	VMOD	0
16	a	a	B-NP	DT	O	17	NMOD	0
17	dose	dose	I-NP	NN	O	15	PMOD	0
18	of	of	B-PP	IN	O	17	NMOD	0
19	125	125	B-NP	CD	O	20	NMOD	0
20	mg/m2	mg/m2	I-NP	NN	O	18	PMOD	0
21	every	every	B-NP	DT	O	22	NMOD	0
22	week	week	I-NP	NN	O	14	VMOD	0
23	for	for	B-PP	IN	O	22	NMOD	0
24	3	3	B-NP	CD	O	25	NMOD	0
25	weeks	week	I-NP	NNS	O	23	PMOD	0
26	.	.	O	.	O	13	P	0

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Of	Of	B-PP	IN	O	14	VMOD	0
4	the	the	B-NP	DT	O	7	NMOD	0
5	13	13	I-NP	CD	O	7	NMOD	0
6	treated	treat	I-NP	VBN	O	7	NMOD	19	treated
7	patients	patient	I-NP	NNS	O	3	PMOD	0
8	,	,	O	,	O	14	P	0
9	10	10	B-NP	CD	O	14	SUB	0
10	(	(	O	(	O	13	DEP	0
11	77	77	B-NP	CD	O	12	NMOD	0
12	%	%	I-NP	NN	O	13	DEP	0
13	)	)	O	)	O	9	NMOD	0
14	had	have	B-VP	VBD	O	1	NMOD	0
15	a	a	B-NP	DT	O	14	OBJ	0
16	radiologically	radiologically	I-NP	RB	O	17	AMOD	0
17	demonstrated	demonstrate	I-NP	VBN	O	15	NMOD	0
18	partial	partial	I-NP	JJ	O	19	NMOD	0
19	response	response	I-NP	NN	O	26	SUB	0
20	and	and	I-NP	CC	O	26	VMOD	0
21	3	3	I-NP	CD	O	26	SUB	0
22	(	(	O	(	O	25	DEP	0
23	23	23	B-NP	CD	O	24	NMOD	0
24	%	%	I-NP	NN	O	25	DEP	0
25	)	)	O	)	O	21	NMOD	0
26	had	have	B-VP	VBD	O	17	VMOD	0
27	stable	stable	B-NP	JJ	O	28	NMOD	0
28	disease	disease	I-NP	NN	O	26	OBJ	0
29	.	.	O	.	O	1	P	0

1	Six	Six	B-NP	CD	O	2	NMOD	0
2	patients	patient	I-NP	NNS	O	7	SUB	0
3	(	(	O	(	O	6	DEP	0
4	46	46	B-NP	CD	O	5	NMOD	0
5	%	%	I-NP	NN	O	6	DEP	0
6	)	)	O	)	O	2	NMOD	0
7	had	have	B-VP	VBD	O	0	ROOT	0
8	a	a	B-NP	DT	O	10	NMOD	0
9	clinical	clinical	I-NP	JJ	O	10	NMOD	0
10	response	response	I-NP	NN	O	7	OBJ	0
11	.	.	O	.	O	7	P	0

1	The	The	B-NP	DT	O	3	NMOD	0
2	median	median	I-NP	JJ	O	3	NMOD	0
3	time	time	I-NP	NN	O	0	ROOT	0
4	to	to	B-PP	TO	O	3	NMOD	0
5	disease	disease	B-NP	NN	O	6	NMOD	0
6	progression	progression	I-NP	NN	O	4	PMOD	0
7	while	while	B-SBAR	IN	O	3	NMOD	0
8	on	on	B-PP	IN	O	10	VMOD	0
9	treatment	treatment	B-NP	NN	O	8	PMOD	0
10	was	be	B-VP	VBD	O	7	SBAR	0
11	24	24	B-NP	CD	O	12	NMOD	0
12	weeks	week	I-NP	NNS	O	10	PRD	0
13	.	.	O	.	O	3	P	0

1	The	The	B-NP	DT	O	4	NMOD	0
2	median	median	I-NP	JJ	O	4	NMOD	0
3	overall	overall	I-NP	JJ	O	4	NMOD	0
4	survival	survival	I-NP	NN	O	5	SUB	0
5	was	be	B-VP	VBD	O	0	ROOT	0
6	27	27	B-NP	CD	O	7	NMOD	0
7	weeks	week	I-NP	NNS	O	5	PRD	0
8	.	.	O	.	O	5	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	disease	disease	I-NP	NN	O	3	SUB	0
3	progressed	progress	B-VP	VBD	O	0	ROOT	0
4	in	in	B-PP	IN	O	3	VMOD	0
5	8	8	B-NP	CD	O	6	NMOD	0
6	patients	patient	I-NP	NNS	O	4	PMOD	0
7	,	,	O	,	O	3	P	0
8	despite	despite	B-PP	IN	O	3	VMOD	0
9	an	an	B-NP	DT	O	11	NMOD	0
10	initial	initial	I-NP	JJ	O	11	NMOD	0
11	response	response	I-NP	NN	O	8	PMOD	0
12	.	.	O	.	O	3	P	0

1	Five	Five	B-NP	CD	O	2	NMOD	0
2	patients	patient	I-NP	NNS	O	3	SUB	0
3	are	be	B-VP	VBP	O	0	ROOT	0
4	still	still	I-VP	RB	O	5	VMOD	0
5	responding	respond	I-VP	VBG	O	3	VC	0
6	to	to	B-PP	TO	O	5	VMOD	0
7	therapy	therapy	B-NP	NN	O	6	PMOD	0
8	.	.	O	.	O	3	P	0

1	Six	Six	B-NP	CD	O	9	SUB	0
2	of	of	B-PP	IN	O	1	NMOD	0
3	the	the	B-NP	DT	O	5	NMOD	0
4	8	8	I-NP	CD	O	5	NMOD	0
5	patients	patient	I-NP	NNS	O	7	NMOD	0
6	whose	whose	B-NP	WP$	O	7	NMOD	0
7	disease	disease	I-NP	NN	O	2	PMOD	0
8	progressed	progress	B-VP	VBN	O	7	NMOD	0
9	have	have	B-VP	VBP	O	0	ROOT	0
10	died	die	I-VP	VBN	O	9	VC	5	died
11	.	.	O	.	O	9	P	0

1	Bevacizumab	Bevacizumab	B-NP	NNP	O	2	SUB	0
2	was	be	B-VP	VBD	O	0	ROOT	0
3	discontinued	discontinue	I-VP	VBN	O	2	VC	19	discontinued
4	in	in	B-PP	IN	O	3	VMOD	0
5	2	2	B-NP	CD	O	6	NMOD	0
6	patients	patient	I-NP	NNS	O	4	PMOD	0
7	because	because	B-PP	IN	O	3	VMOD	0
8	of	of	I-PP	IN	O	7	PMOD	0
9	nonfatal	nonfatal	B-NP	JJ	O	11	NMOD	0
10	intracranial	intracranial	I-NP	JJ	O	11	NMOD	0
11	bleeding	bleeding	I-NP	NN	O	7	PMOD	0
12	.	.	O	.	O	2	P	0

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	The	The	B-NP	DT	O	4	NMOD	0
4	combination	combination	I-NP	NN	O	9	SUB	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	bevacizumab	bevacizumab	B-NP	NN	O	8	NMOD	0
7	and	and	I-NP	CC	O	8	NMOD	0
8	irinotecan	irinotecan	I-NP	NN	O	5	PMOD	0
9	is	be	B-VP	VBZ	O	1	NMOD	0
10	safe	safe	B-ADJP	JJ	O	9	PRD	0
11	and	and	O	CC	O	9	VMOD	0
12	has	have	B-VP	VBZ	O	9	VMOD	0
13	excellent	excellent	B-NP	JJ	O	14	NMOD	0
14	activity	activity	I-NP	NN	O	12	OBJ	0
15	even	even	B-ADVP	RB	O	16	PMOD	0
16	in	in	B-PP	IN	O	9	VMOD	0
17	this	this	B-NP	DT	O	22	NMOD	0
18	relapsed	relapse	I-NP	VBN	O	21	AMOD	0
19	,	,	I-NP	,	O	21	P	0
20	heavily	heavily	I-NP	RB	O	21	AMOD	0
21	pretreated	pretreated	I-NP	JJ	O	22	NMOD	19	pretreated
22	population	population	I-NP	NN	O	16	PMOD	0
23	of	of	B-PP	IN	O	22	NMOD	0
24	patients	patient	B-NP	NNS	O	33	SUB	0
25	with	with	B-PP	IN	O	24	NMOD	0
26	high-grade	high-grade	B-NP	JJ	O	28	NMOD	0
27	malignant	malignant	I-NP	JJ	O	28	NMOD	0
28	glioma	glioma	I-NP	NN	O	25	PMOD	0
29	,	,	O	,	O	24	P	0
30	most	most	B-NP	JJS	O	33	SUB	0
31	of	of	B-PP	IN	O	30	NMOD	0
32	whom	whom	B-NP	WP	O	31	PMOD	0
33	would	would	B-VP	MD	O	23	SBAR	0
34	not	not	I-VP	RB	O	33	VMOD	0
35	be	be	I-VP	VB	O	33	VC	0
36	candidates	candidate	B-NP	NNS	O	35	PRD	0
37	for	for	B-PP	IN	O	36	NMOD	0
38	clinical	clinical	B-NP	JJ	O	39	NMOD	0
39	trials	trial	I-NP	NNS	O	37	PMOD	0
40	.	.	O	.	O	1	P	0

